Patents by Inventor William P. Tong

William P. Tong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110312007
    Abstract: Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (I) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.
    Type: Application
    Filed: August 1, 2011
    Publication date: December 22, 2011
    Inventors: Sabrina M. Ronen, Juri G. Gelovani, William G. Bornmann, Jihai Pang, Ashutosh Pal, William P. Tong, David S. Maxwell, Madhuri Sankaranarayanapillai
  • Publication number: 20100062465
    Abstract: Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (1) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.
    Type: Application
    Filed: April 20, 2007
    Publication date: March 11, 2010
    Inventors: Sabrina M. Ronen, Juri G. Gelovani, William G. Bornmann, Jihai Pang, Ashutosh Pal, William P. Tong, Ashutosh Paz, William P. Tong, David S. Maxwell, Madhuri Sankaranarayanapillai
  • Patent number: 6515022
    Abstract: Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the treatment of fibrotic lung disease, emphysema, and the prevention and treatment of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: February 4, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: William P. Tong, Raymond P. Warrell, Jr.
  • Publication number: 20020035152
    Abstract: Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the treatment of fibrotic lung disease, emphysema, and the prevention and treatment of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
    Type: Application
    Filed: May 11, 2001
    Publication date: March 21, 2002
    Inventors: William P. Tong, Raymond P. Warrell
  • Patent number: 6251941
    Abstract: Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the prevention of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: June 26, 2001
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: William P. Tong, Raymond P. Warrell